Abstract: Tricylic ether carbamates that inhibit HIV proteolytic enzymes and processes for preparing the compounds are describes. Methods of using the disclosed compounds for treating patients infected with HIV are also described.

Abstract: C3-functionalized-cyclopentanyltetrahydrofuranyl carbamates that inhibit HIV proteolytic enzymes and processes for preparing the compounds are described. Compositions comprising the disclosed compound and methods of using the compounds and/or compositions for treating patients infected with HIV are also described.

Abstract: The present invention provides a monoclonal antibody that recognizes the V3 loop of the envelope glycoprotein gp120 of AIDS virus, which is any one selected from the following antibodies: (a) an antibody having the amino acid sequence shown in SEQ ID NO: 1 as the amino acid sequence of a H chain variable region (VH), and having the amino acid sequence shown in SEQ ID NO: 2 as the amino acid sequence of a L chain variable region (VL); and (b) an antibody having the amino acid sequence shown in SEQ ID NO: 3 as the amino acid sequence of a H chain variable region (VH), and having the amino acid sequence shown in SEQ ID NO: 4 as the amino acid sequence of a L chain variable region (VL).

Abstract: A sulfur trioxide decomposition catalyst, in particular, a sulfur trioxide decomposition catalyst capable of lowering the temperature required when producing hydrogen by an S—I cycle process is disclosed. A sulfur trioxide decomposition catalyst that includes a composite oxide of tungsten, vanadium and at least one metal selected from the group consisting of transition metal and rare earth elements is provided. Also, a sulfur dioxide production process that includes decomposing sulfur trioxide into sulfur dioxide and oxygen by using the sulfur trioxide decomposition catalyst above is provided. Furthermore, a hydrogen production process, wherein the reaction of decomposing sulfur trioxide into sulfur dioxide and oxygen by an S—I cycle process is performed by the above-described sulfur dioxide production process is provided.

Abstract: An acoustic signal processing device includes a frequency domain transform unit configured to transform an acoustic signal to a frequency domain signal for each channel, a filter coefficient calculation unit configured to calculate at least two sets of filter coefficients of a filter for each section having a predefined number of frames with respect to a sampled signal obtained by sampling the frequency domain signal transformed by the frequency domain transform unit for each frame such that the magnitude of a residual calculated based on a filter compensating for the difference in transfer characteristics between the channels of the acoustic signal is minimized, and an output signal calculation unit configured to calculate an output signal of a frequency domain based on the frequency domain signal transformed by the frequency domain transform unit and at least two sets of filter coefficients calculated by the filter coefficient calculation unit.

Abstract: It is an object of the present invention to provide a novel mitochondrial function-improving agent and a novel PGC-1? expression inducing agent. The present invention provides a mitochondrial function-improving agent and a PGC-1? expression inducing agent each of which comprises a lysine-specific demethylase-1 (LSD-1) inhibitor.

Abstract: An objective is to provide screening methods for substances having an activity of promoting maturation into hemocytes. It was revealed that in the maturation process of erythrocytes and platelets, RP S19 multimers are released to the outside of the cell and act on the C5a receptors of erythroblasts and megakaryocytes, thereby causing maturation of erythroblasts and megakaryocytes to erythrocytes and platelets. Based on such findings, the present invention provides methods of screening for substances having an activity of promoting maturation into hemocytes by targeting the RP S19 multimers and C5a receptors. The screening methods of the present invention can detect hemocyte maturation using an increase of the R4 RGS family as an indicator. Furthermore, the present invention provides agents for promoting hemocyte maturation, which comprise RP S19 multimers and a substance having an activity of promoting maturation into hemocytes as useful components.

Abstract: The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.

Abstract: The invention relates to a method of treating ocular amyloidosis by reducing TTR expression in a subject by administering a double-stranded ribonucleic acid (dsRNA) that targets a TTR gene to the retinal pigment epithelium of the subject.

Abstract: Tricylic ether carbamates that inhibit HIV proteolytic enzymes and processes for preparing the compounds are described. Methods of using the disclosed compounds for treating patients infected with HIV are also described.

Abstract: A method of producing a Group II-VI compound semiconductor. The method involves generating a pulsed electrical discharge plasma between metallic electrodes in sulfur to produce a Group II-VI compound semiconductor. A method of producing a Group II-VI compound semiconductor phosphor using a pulsed electrical discharge plasma. A hexagonal crystal of Group II-VI compound semiconductor composed of a plurality of twin crystals.

Abstract: It is an object of the present invention to provide a method for producing a cell medicine that is effective for diseases while causing a low risk to these diseases. The present invention provides a method for producing a phagocyte that expresses a foreign protein, which comprises: a step of introducing a protein expression vector into an induced pluripotent stem cell; and a step of inducing the induced pluripotent stem cell, into which the protein expression vector has been introduced, to differentiate into a phagocyte.

Abstract: A method of treating food capable of easily softening or pulverizing food in a short time without losing nutrients is provided. A shock wave (SW) generated in a shock wave source is applied to food such as an apple or tea leaves to soften or pulverize the food. A large mechanical load is not necessary, so the food is easily softened or pulverized. Moreover, it is not necessary to heat the food, so the food is softened or pulverized in a short time without losing nutrients in the food due to heat during heating.

Abstract: It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.

Abstract: An object of the present invention is to provide a method of producing a myeloid blood cell possessing a proliferative capability. According to the present invention, provided is a method of producing a myeloid blood cell possessing a proliferative capability, including forcedly expressing (A) a cMYC gene, and (B) at least one gene selected from the group consisting of a BMI1 gene, an EZH2 gene, an MDM2 gene, an MDM4 gene, and an HIF1A gene in a myeloid blood cell.

Abstract: Previously, it was difficult to obtain high-affinity antibodies that specifically bind to HMGB-1 but not to HMGB-2. Under this circumstance, the present inventors successfully obtained antibodies that are more reactive to HMGB-1 than to HMGB-2 by using specific peptides as an antigen. The present inventors also demonstrated that the antibodies had a HMGB-1-neutralizing activity. The present inventors administered the antibodies to amyloidosis model animals, and as a result, successfully demonstrated that the antibodies produced a significant therapeutic effect.

Abstract: The present invention aims to provide hepatitis C virus inhibitors capable of inhibiting viral replication in hepatitis C virus-infected cells. The replication of hepatitis C virus can be inhibited and hepatitis C virus-infected cells can be specifically injured by specifically inhibiting BGT-1 or AKR1C1 involved in the replication of hepatitis C virus. Thus, viral inhibitors comprising a substance inhibiting BGT-1 or AKR1C1 are effective for the treatment of hepatitis C.

Abstract: A vibration damping device for suppressing vibrations of a structure includes: a slide body mechanism having a concave slide body and a convex slide body which are fixed to the structure and are arranged so as to be slidable relative to each other in a reciprocating manner; and a biasing means which pushes the slide bodies to each other. Each slide body has: a first slide surface having a shape which increases a height of the slide body mechanism 2 along with the increase of a displacement amount of the slide body in one sliding direction from a neutral position relative to the counterpart slide body; and a second slide surface having a shape by which the height of the slide body mechanism is increased along with the increase of the displacement of the slide body in the other sliding direction from the neutral position.

Abstract: There is provided a novel loxoprofen derivative that has no side effect such as a gastrointestinal disorder and also has excellent anti-inflammatory and analgesic effects and is represented by the following formula (I) or (II): (wherein R1 and R2 each represent a halogen atom or a substituted or unsubstituted phenyl group) or a pharmacologically acceptable salt thereof. In the derivative, the halogen atom is selected from a chlorine atom, a bromine atom, a fluorine atom, and an iodine atom, and a substituent of the substituted phenyl group is a halogen atom, a hydroxyl group, a substituted or unsubstituted lower alkyl group, a lower alkylthio group, a lower alkoxy group, a nitro group, an amino group, or a carboxyl group.

Abstract: To provide a method of welding a metallic glass and a crystalline metal by shifting a high-energy beam scan area from a butting face thereof to the metallic glass side, to fall within a composition range required for glass phase formation of a metallic glass base material in a simplified assured manner. In a welding method for weldingly joining a metallic glass and a crystalline metal together by scanning a high-energy beam in a position shifted from a butt interface between the metallic glass and the crystalline metal toward the metallic glass, it is intended to provide a technique for allowing a composition of a melt zone formed around a welding interface to fall within a composition range required for forming a glass phase in the metallic glass to be joined, in a simple and more reliable manner. A metallic glass (1) and a crystalline metal (2) are butted against each other to define a groove space (Y) over a groove formed on the side of the crystalline metal (2).